1.    Schaller JG. Enfermedad de Kawasaki. In: Behrman R, Kliegman R, Arvin A. Nelson Tratado de Pediatría. 15º ed. México: Interamericana. Mc Graw-Hill. 1997: 850-2.

2.    Cassidy J, Petty R. Vasculitis. In: Cassidy J, Petty R. Textbook of Pediatric Rheumatology. 3ª ed. Philadelphia: WB Saunders, 1995: 372-83.

3.    Caggiani M, Rubio I, Parada P, Lagomarsino G, Guidobono G, Mañé Garzón F. Enfermedad de Kawasaki. A propósito de un caso. Arch Pediatr Urug 1989; 60 (1-4): 65-8.

4.    Shulman ST, De Inocencio J, Hirsch R. Enfermedad de Kawasaki. Clin Pediatr Norteam 1995; 5: 1133-50.

5.    Rowley A, Shulman S. Kawasaki Syndrome. In: Gessner I, Victorica B. Pediatric Cardiology, a Problem Oriented Approach. Philadelphia: WB Saunders, 1993: 191-200.

6.    Rowley A, Shulman S. Síndrome de Kawasaki. Clin Pediatr Norteam 1999; 2: 341-59.

7.    Laupland K, Dele Davis H. Epidemiology, Etiology and Management of Kawasaki Disease: State of de Art. Pediatr Cardiol 1999; 20: 177-83.

8.    Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, et al. Result of the Nationwide Epidemiologic Survey of Kawasaki Disease in 1995 and 1996 in Japan. Pediatrics 1998; 102(6): e65.

9.    Barbour A, Krueger G, Feorino P, Smith C. Kawasaki-like Disease in a Young Adult. Association With Primary Epstein-Barr Virus Infection. JAMA 1979; 241(4): 397-9.

10.    Morens D. Center for Disease Control. Atlanta. Thoughts on Kawasaki Disease Etiology. JAMA 1979; 241(4): 399.

11.    Iwanaga M, Takada K, Osato T, Saeki Y, Noro S, Sakurada N. Kawasaki Disease and Epstein-Barr Virus. Lancet 1981; 1: 938-9.

12.    Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, et al. Epstein-Barr Virus Genome-Positive T Lymphocytes in a Boy with Chronic Active EBV Infection Associated with Kawasaki-like Disease. Nature 1988; 333: 455-7.

13.    Okano M, Hase N, Sakiyama Y, Matsumoto S. Long Term Observation in Patients With Kawasaki Syndrome and Their Relation to Epstein-Barr Virus Infection. Pediatr Infect Dis J 1990; 9(2): 139-41.

14.    Marchette N, Melish M, Hicks R, Kihara S, Sam E, Ching D. Epstein-Barr Virus and Other Herpesvirus Infections in Kawasaki Syndrome. J Infect Dis 1990; 161: 680-4.

15.    Kikuta H, Matsumoto S, Osato T. Kawasaki Disease and Epstein-Barr Virus. Acta Paediatr Jpn 1991; 33: 765-70.

16.    Kikuta H, Nakanishi M, Ishikawa N, Cono M, Matsumoto S. Detection of Epstein-Barr Virus Sequences in Patiens with Kawasaki Disease by Means of the Polymerase Chain Reaction. Itervirology 1992; 33: 1-5.

17.    Kikuta H, Sakiyama Y, Matsumoto S, Hamada I, Yazaki M, Iwaki T, et al. Detection of Epstein-Barr Virus DNA in Cardiac and Aortic Tissues from Chronic, Active Epstein-Barr Virus Infection Associated with Kawasaki Disease-like Coronary Artery Aneurysms. J Pediatr 1993; 123: 90-2.

18.    Plotkin S. Mononucleosis Infecciosa. In: Behrman R, Kliegman R. Nelson Tratado de Pediatría. 14ª ed. México: Interamericana. Mc Graw-Hill. 1992: 979-82.

19.    American Academy of Pediatrics. Infecciones por Virus de Epstein-Barr. In: Peter G. Red Book Report of the Committee of Infections Diseases. 24th ed. Elk Grove Village: American Academy of Pediatrics, 1999: 611-5.

20.    Katz B, Miller G. Infecciones por el Virus de Epstein-Barr. In: Katz S, Gershon A, Hotez P. Krugman Enfermedades Infecciosas Pediátricas. 10ª ed. México: Harcourt España. 1999: 98-115.

21.    Peter J, Ray G. Mononucleosis Infecciosa. Pediatrics in Review 1998; 19(8): 307-10.

22.    Newburger JW, Takahashi M, Burns JC, et al. The Treatment of Kawasaki Syndrome with Intravenous Gammaglobulin. N Engl J Med 1986; 315: 341-7.

23.    Newburger JW, Takahashi M, Beiser AS, et al. A Single Intravenous Infusion of Gamma Globulin al Compared with four Infusions in the Treatment of Acute Kawasaki Syndrome. N Engl J Med 1991; 324: 1633-9.

24.    Casteels-Van Daele M, Gaetano G. Purpura and Acetylsalicylic Acid Therapy. Acta Paediat Scand 1971; 60: 203-8.

25.    Klaassen CD. Principios de Toxicología. In: Goodman Gilman A, Goodman L, Rall T, Murad F. Las Bases Farmacológicas de la Terapéutica. 7º ed. México: Médica Panamericana. 1986: 1507-19.

26.    Laporte JR, Capella D. Mecanismos de producción y diagnóstico clínico de los efectos indeseables producidos por medicamentos. in: Laporte JR, Tognoni G. Principios de Epidemiología del Medicamento. 2ª ed. Barcelona: Masson- Salvat, 1993: 95-109.

27.    Martindale. Part I. Analgesics and Anti-inflammatory Drugs and Antipyretics. Martindale. The Complete Drug Reference. 32ª ed. London: Pharmaceutical Press, 1999: 1-7.

28.    Linakis J, Lovejoy F. Antipyretics. In: Yaffe A. Pediatric Pharmacology. Therapeutic Principles in Practice. 2ª ed. Philadelphia: WB Saunders, 1992: 335-44.

29.    Comité de Expertos. International drug monitoring: the role of national centers. Technical Report Series Nº 498. Ginebra: Organización Mundial de la Salud, 1972.

30.    Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Sistema Nacional de Farmacovigilancia. 1993; 1: 6.